Christopher Fenimore - Regeneron Pharmaceuticals Vice President Controller
| REGN Stock | USD 749.51 11.51 1.56% |
President
Mr. Christopher Fenimore is Vice President, Controller of the Company. He was Vice President, Controller since March 2017. From January 2017 to March 2017, he served as Vice President, Deputy Controller, and previously served as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance at Mojave Therapeutics, Inc. Mr. Fenimore prior experience includes working as a supervising senior accountant at KPMG, as well as healthcare industryfocused VC and investment banking roles. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York. since 2017.
| Age | 53 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 |
| Phone | 914 847 7000 |
| Web | https://www.regeneron.com |
Regeneron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0741 % which means that it generated a profit of $0.0741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1717 %, meaning that it created $0.1717 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 197.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Dashyant Dhanak | Incyte | 63 | |
| Camilla Sylvest | Novo Nordisk AS | 52 | |
| Karsten Knudsen | Novo Nordisk AS | 53 | |
| Suma Krishnan | Krystal Biotech | 59 | |
| Michael Benkowitz | United Therapeutics | 52 | |
| Xiaobin Wu | BeiGene | 62 | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Frank Bennett | Ionis Pharmaceuticals | 67 | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Maziar Doustdar | Novo Nordisk AS | 54 | |
| Wade Walke | Ionis Pharmaceuticals | N/A | |
| Laura SeppLorenzino | Intellia Therapeutics | 63 | |
| Douglas Langa | Novo Nordisk AS | 58 | |
| Henrik Wulff | Novo Nordisk AS | 54 | |
| Doug Langa | Novo Nordisk AS | 52 | |
| Ludovic Helfgott | Novo Nordisk AS | 50 | |
| Erik Harris | Ultragenyx | 54 | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Kevin Fitzgerald | Alnylam Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0741 |
Regeneron Pharmaceuticals Leadership Team
Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph JD, General VP | ||
| Marion McCourt, Senior Vice President and Head of Commercial | ||
| Patrice Gilooly, Senior Operations | ||
| Andrew Murphy, Executive Research | ||
| Christopher CPA, Head Finance | ||
| Joseph LaRosa, Senior Vice President General Counsel, Secretary | ||
| Bob McCowan, Senior Officer | ||
| Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply | ||
| Gerald Underwood, Senior Operations | ||
| Christina Chan, Senior Affairs | ||
| Robert Landry, CFO and Sr. VP of Fin. | ||
| Melissa Lozner, Senior Officer | ||
| Ryan Crowe, Senior Analysis | ||
| Christopher Fenimore, Vice President Controller |
Regeneron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0741 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 74.01 B | ||||
| Shares Outstanding | 108.07 M | ||||
| Shares Owned By Insiders | 1.56 % | ||||
| Shares Owned By Institutions | 90.91 % | ||||
| Number Of Shares Shorted | 1.85 M | ||||
| Price To Earning | 15.51 X |
Pair Trading with Regeneron Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Regeneron Stock
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.87 | VALN | Valneva SE ADR | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Regeneron Stock
| 0.61 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.57 | KZR | Kezar Life Sciences | PairCorr |
| 0.47 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.41 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.44 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.